See More Hear More Watch More Hear More Get on iTunes
WSJ Daily Minute WSJMinute

Valeant bid for Allegan under scrutiny

Allergan’s fight against Valeant Pharmaceuticals’ $53 billion takeover bid highlights the acquirer’s hard-nosed strategy: buy up companies, shed most of their research operations, and make money selling their products.


More from